Rosetta Revises Deal with Precision to Co-market miRview mets2
October 17, 2012
Rosetta Revises Deal with Precision to Co-market miRview mets2
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Rosetta Genomics Restructures, Eliminating 35 Positions
October 11, 2011 / GenomeWeb Daily News - Rosetta Genomics' 2012 Revenues Nearly Double
March 25, 2013 / GenomeWeb Daily News - Underwriters Exercise Option on Rosetta Public Offering; Total Gross Proceeds Rise to $31.6M
August 29, 2012 / GenomeWeb Daily News - Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012 / GenomeWeb Daily News - Rosetta Publishes Data on Cancer of Unknown Primary Origin Test
May 31, 2012 / Gene Silencing News